The Silicon Valley Journal recently listed upcoming Bay Area IPOs, 5 of which are life science companies. None went public this week, nor are they expected to go public before June.
The life science companies:
“CardioDX, $92 million: This Palo Alto cardiovascular genomics company led by CEO David Levison didn’t say in its April 29 filing how much it hopes to raise. But plans it pulled in November were to raise up to $92 million. “
“ProteinSimple, $86.25 million: This Santa Clara bioscience company led by CEO Tim Harkness disclosed its plans on May 1. It has created protein analysis tools to help researchers understand the role of proteins in disease.”
“Ardelyx, $69 million: This Fremont biotech led by CEO Michael Raab disclosed its IPO plans on May 19. It develops small molecule treatments for kidney an gastrointestinal disease.”
“Ariosa Diagnostics, $68.4 million: The target number for this San Jose prenatal genetic testing company led by Dr. Kenneth Song is actually uncertain.”
“KineMed, $51 million: This Emeryville-based company makes biomarkers used by pharmaceutical companies in drug development.”